A new approach for pharmacokinetics of single-dose cetuximab in rhesus monkeys by surface plasmon resonance biosensor.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of Pharmaceutical and Biomedical Analysis

• Publication date

  2009-09-08

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.jpba.2009.04.009PMID 19446977
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 3040 POSTER Optimal dose for an every 2 week (q2w) cetuximab (C) regimen in patients (pts) with metastatic colorectal cancer (mCRC): a phase I safety, pharmacokinetics (PK) and pharmacodynamics (PD) study of weekly (q1w) and q2w schedules

  2007cited by this paper
• Detection of fungal spores using a generic surface plasmon resonance immunoassay.

  2007cited by this paper
• 3017 POSTER Cetuximab dose-escalation in patients (pts) with metastatic colorectal cancer (mCRC) with no or slight skin reactions on standard treatment: pharmacokinetic (PK), pharmacodynamic (PD) and efficacy data from the EVEREST study

  2007cited by this paper
• In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR

  2006cited by this paper
• Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer.

  2006cited by this paper
• Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.

  2005cited by this paper
• Development and validation of an optical SPR biosensor assay for tylosin residues in honey.

  2005cited by this paper
• Epidermal growth factor receptor inhibitors in cancer treatment.

  2005cited by this paper
• Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study.

  2005cited by this paper
• Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma.

  2005cited by this paper
• Antitumor effect and enhancement of cytotoxic drug activity by cetuximab in nasopharyngeal carcinoma cells.

  2005cited by this paper
• Determination of concentration and binding affinity of antibody fragments by use of surface plasmon resonance.

  2005cited by this paper
• Phase II Study of Gefitinib in Patients with Relapsed or Persistent Ovarian or Primary Peritoneal Carcinoma and Evaluation of Epidermal Growth Factor Receptor Mutations and Immunohistochemical Expression: A Gynecologic Oncology Group Study

  2005cited by this paper
• Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

  2004cited by this paper
• Role of an Anti-epidermal Growth Factor Receptor in Treating Cancer

  2004cited by this paper
• 552 Evaluation of the pharmacokinetic (PK) interactions between cetuximab and irinotecan in patients with epidermal growth factor receptor (EGFR)-expressing advanced solid tumors. Results of a phase I study

  2003cited by this paper
• Development and validation of a biosensor-based immunoassay for progesterone in bovine milk.

  2002cited by this paper
• Targeting the epidermal growth factor receptor for cancer therapy.

  2002cited by this paper
• Chemoprevention of breast cancer: a model for change.

  2002cited by this paper
• Detection of streptomycin residues in whole milk using an optical immunobiosensor.

  2001cited by this paper
• A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.

  2001cited by this paper
• Principles of BIACORE

  2000cited by this paper
• Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice.

  1998cited by this paper
• Expression of epidermal growth factor and androgen receptors in ovarian cancer.

  1997cited by this paper
• EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients.

  1997cited by this paper
• The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer.

  1996cited by this paper
• The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma.

  1996cited by this paper
• Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model.

  1995cited by this paper
• Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts.

  1993cited by this paper

• Cross-Species Extrapolation of Neonatal Fc Receptor (FcRn) Binding Affinity to Predict Monoclonal Antibody Pharmacokinetics in Humans Using Physiologically Based Pharmacokinetic Modeling (PBPK): Are We There Yet?

  2025cites this paper
• Protective Effect of Crocin on Endothelial Cells Integrity: Studied by Surface Plasmon Resonance

  2022cites this paper
• A Single Animal Species-Based Prediction of Human Clearance and First-in-Human Dose of Monoclonal Antibodies: Beyond Monkey

  2021cites this paper
• A Critical Review of Properties and Analytical/Bioanalytical Methods for Characterization of Cetuximab

  2020influential citation
• Predicting Method for the Human Plasma Concentration-Time Profile of a Monoclonal Antibody from the Half-life of Non-human Primates.

  2020cites this paper
• Identification of eupatilin and ginkgolide B as p38 ligands from medicinal herbs by surface plasmon resonance biosensor-based active ingredients recognition system.

  2019cites this paper
• Development of a Gold Nanoparticle–Functionalized Surface Plasmon Resonance Assay for the Sensitive Detection of Monoclonal Antibodies and Its Application in Pharmacokinetics

  2019cites this paper
• Comparative safety assessments of the biosimilar APZ001 and Erbitux in pre-clinical animal models.

  2018cites this paper
• Mammalian Cell Line Selection Strategies for High-Producers

  2015cites this paper
• Investigation of phase SPR biosensor for efficient targeted drug screening with high sensitivity and stability

  2015cites this paper
• Recent advances in the bioanalysis of peptide and protein therapeutics

  2013cites this paper
• Bioanalysis of Biotherapeutics

  2013cites this paper
• Quantum-dot-based biosensor for simultaneous detection of biomarker and therapeutic drug: first steps toward an assay for quantitative pharmacology.

  2012cites this paper
• Practical quantitative and kinetic applications of bio-layer interferometry for toxicokinetic analysis of a monoclonal antibody therapeutic.

  2012cites this paper
• European Medicines Agency workshop on biosimilar monoclonal antibodies

  2009cites this paper